Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3Kα-Akt signaling.

Yang L, Cai X, Liu J, Jia Z, Jiao J, Zhang J, Li C, Li J, Tang XD.

PLoS One. 2013 Apr 30;8(4):e62373. doi: 10.1371/journal.pone.0062373. Print 2013.

2.

The toll-like receptor 9 agonist, CpG-oligodeoxynucleotide 1826, ameliorates cardiac dysfunction after trauma-hemorrhage.

Zhang X, Gao M, Ha T, Kalbfleisch JH, Williams DL, Li C, Kao RL.

Shock. 2012 Aug;38(2):146-52. doi: 10.1097/SHK.0b013e31825ce0de.

3.

CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia/reperfusion injury: involving activation of PI3K/Akt signaling.

Cao Z, Ren D, Ha T, Liu L, Wang X, Kalbfleisch J, Gao X, Kao R, Williams D, Li C.

Biochim Biophys Acta. 2013 Jan;1832(1):96-104. doi: 10.1016/j.bbadis.2012.08.008. Epub 2012 Aug 16.

4.

Postconditioning with a CpG containing oligodeoxynucleotide ameliorates myocardial infarction in a murine closed-chest model.

Kim SC, Wu S, Fang X, Neumann J, Eichhorn L, Schleifer G, Boehm O, Meyer R, Frede S, Hoeft A, Baumgarten G, Knuefermann P.

Life Sci. 2014 Dec 5;119(1-2):1-8. doi: 10.1016/j.lfs.2014.09.029. Epub 2014 Oct 29.

PMID:
25445440
5.

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.

Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA.

Nat Med. 2005 Feb;11(2):214-22. Epub 2005 Jan 23.

PMID:
15665834
6.

The Toll-like receptor 9 ligand, CpG oligodeoxynucleotide, attenuates cardiac dysfunction in polymicrobial sepsis, involving activation of both phosphoinositide 3 kinase/Akt and extracellular-signal-related kinase signaling.

Gao M, Ha T, Zhang X, Wang X, Liu L, Kalbfleisch J, Singh K, Williams D, Li C.

J Infect Dis. 2013 May 1;207(9):1471-9. doi: 10.1093/infdis/jit036. Epub 2013 Jan 28.

7.

Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes.

Liu L, Zhao X, Pierre SV, Askari A.

Am J Physiol Cell Physiol. 2007 Nov;293(5):C1489-97. Epub 2007 Aug 29.

9.

Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways.

Clemente CF, Xavier-Neto J, Dalla Costa AP, Consonni SR, Antunes JE, Rocco SA, Pereira MB, Judice CC, Strauss B, Joazeiro PP, Matos-Souza JR, Franchini KG.

J Mol Cell Cardiol. 2012 Feb;52(2):493-501. doi: 10.1016/j.yjmcc.2011.10.015. Epub 2011 Oct 26.

PMID:
22056317
10.

Small heat-shock protein Hsp20 attenuates beta-agonist-mediated cardiac remodeling through apoptosis signal-regulating kinase 1.

Fan GC, Yuan Q, Song G, Wang Y, Chen G, Qian J, Zhou X, Lee YJ, Ashraf M, Kranias EG.

Circ Res. 2006 Nov 24;99(11):1233-42. Epub 2006 Oct 26.

11.

Exercise training and PI3Kα-induced electrical remodeling is independent of cellular hypertrophy and Akt signaling.

Yang KC, Tseng YT, Nerbonne JM.

J Mol Cell Cardiol. 2012 Oct;53(4):532-41. doi: 10.1016/j.yjmcc.2012.07.004. Epub 2012 Jul 21.

12.

Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling.

Ai W, Zhang Y, Tang QZ, Yan L, Bian ZY, Liu C, Huang H, Bai X, Yin L, Li H.

J Cell Biochem. 2010 Aug 1;110(5):1111-22. doi: 10.1002/jcb.22623.

PMID:
20564207
13.

Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy.

Kemi OJ, Ceci M, Wisloff U, Grimaldi S, Gallo P, Smith GL, Condorelli G, Ellingsen O.

J Cell Physiol. 2008 Feb;214(2):316-21.

PMID:
17941081
14.

Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function.

Rigor DL, Bodyak N, Bae S, Choi JH, Zhang L, Ter-Ovanesyan D, He Z, McMullen JR, Shioi T, Izumo S, King GL, Kang PM.

Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H566-72. doi: 10.1152/ajpheart.00562.2008. Epub 2009 Jan 2.

15.

Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-alpha signaling.

Lim EJ, Lee SH, Lee JG, Chin BR, Bae YS, Kim JR, Lee CH, Baek SH.

FEBS Lett. 2006 Aug 7;580(18):4533-8. Epub 2006 Jul 17.

16.

Erythropoietin attenuates hypertrophy of neonatal rat cardiac myocytes induced by angiotensin-II in vitro.

Wen Y, Zhang XJ, Ma YX, Xu XJ, Hong LF, Lu ZH.

Scand J Clin Lab Invest. 2009;69(4):518-25. doi: 10.1080/00365510902802286.

PMID:
19347742
17.
18.

Pivotal role of ADP-ribosylation factor 6 in Toll-like receptor 9-mediated immune signaling.

Wu JY, Kuo CC.

J Biol Chem. 2012 Feb 3;287(6):4323-34. doi: 10.1074/jbc.M111.295113. Epub 2011 Dec 14.

19.

Interplay between the E2F pathway and β-adrenergic signaling in the pathological hypertrophic response of myocardium.

Major JL, Salih M, Tuana BS.

J Mol Cell Cardiol. 2015 Jul;84:179-90. doi: 10.1016/j.yjmcc.2015.04.026. Epub 2015 May 2.

PMID:
25944088
20.

Isorhamnetin protects against cardiac hypertrophy through blocking PI3K-AKT pathway.

Gao L, Yao R, Liu Y, Wang Z, Huang Z, Du B, Zhang D, Wu L, Xiao L, Zhang Y.

Mol Cell Biochem. 2017 May;429(1-2):167-177. doi: 10.1007/s11010-017-2944-x. Epub 2017 Feb 7.

PMID:
28176246

Supplemental Content

Support Center